Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Ensysce Biosciences Q2 EPS $(0.79) Beats $(1.18) Estimate, Sales $1.371M Beat $650.000K Estimate

Author: Benzinga Newsdesk | August 13, 2025 03:20pm
Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(1.18) by 33.05 percent. This is a 76.06 percent increase over losses of $(3.30) per share from the same period last year. The company reported quarterly sales of $1.371 million which beat the analyst consensus estimate of $650.000 thousand by 110.92 percent. This is a 654.14 percent increase over sales of $181.797 thousand the same period last year.

Posted In: ENSC


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist